What it is.
Urolithin A presented as a planned single-ingredient capsule with source-linked research context.
Urolithin A is a defined ingredient. Nutrae keeps its planned capsule specification separate from studies of proprietary formulations.
What researchers measured.
Human studies used specific Urolithin A formulations and reported mixed study-specific outcomes. They do not test the planned Nutrae capsule.
Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial
Design: Randomized, double-blind, placebo-controlled trial · 66 adults aged 65 to 90 years
Form, dose and duration: Proprietary urolithin A formulation · 1,000 mg/day · 4 months
Reported result: The primary six-minute-walk and maximal ATP-production outcomes were not significantly better than placebo. Selected muscle-endurance measures improved versus placebo at two months, but not consistently at four months because of placebo-group improvement. Some biomarkers improved.
Important limit: Small trial, all participants were White, COVID-related disruption occurred and selected positive secondary findings require confirmation.
Primary recordUrolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults
Design: Randomized, double-blind, placebo-controlled trial · 88 healthy overweight middle-aged adults randomized; 79 completed
Form, dose and duration: Proprietary urolithin A formulation · 500 or 1,000 mg/day · 4 months
Reported result: The primary peak-power outcome did not improve significantly. Hamstring average torque improved by approximately 12% with 500 mg and 9.8% with 1,000 mg versus placebo, and maximum flexion torque improved by approximately 10.6% and 10.5%. Broader quadriceps, handgrip, walking and aerobic outcomes were mostly not significant between groups.
Important limit: Some positive findings were secondary endpoints, the sample was modest, and the studied proprietary formulation is not automatically equivalent to Nutrae's capsule.
Primary recordEffects of Urolithin A Supplementation on Muscle Health Outcomes in Humans from Randomized Controlled Trials
Design: Systematic review and meta-analysis of randomized controlled trials · 5 randomized trials with 236 participants
Form, dose and duration: Urolithin A formulations used across the included trials, predominantly proprietary formulations · Varied across included studies, generally within 250 to 1,000 mg/day · Short-term trials up to approximately 4 months
Reported result: Only the six-minute-walk outcome could be pooled: mean difference 17.03 metres, 95% confidence interval -5.33 to 39.40, p=0.135, I-squared 0%. Other strength, endurance and biomarker signals were heterogeneous and exploratory.
Important limit: Only five heterogeneous trials, small samples, short durations and substantial reliance on company-sponsored proprietary formulations.
Primary recordWhat this does not prove.
Principal trials used proprietary formulations. Equal nominal milligrams do not establish equal exposure or clinical equivalence for a finished Nutrae capsule.
No finished Nutrae product has been tested in a randomized human trial. Ingredient studies do not establish an outcome for this capsule or show that it produces the same exposure as another formulation.
Use the final label.
Urolithin A was generally well tolerated in relatively small, short human studies. Longer-term safety, uncommon adverse effects and medicine interactions remain less certain.
- Most human safety data come from small, short studies using proprietary formulations.
- Pregnancy, nursing, medicine use, medical conditions and planned surgery require qualified medical advice.